INSMED Inc (INSM) stock
INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30136% above fair value
$144.46+24.66 (+20.58%)
Close on Nov 19, 2026Market cap $31.69BP/E –Yield –
Insmed free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Insmed's free cash flow for the twelve months ending Sep 30, 2026 was -$627.58M. For fiscal 2025 it was -$967.58M. The highest annual figure on record is -$7.72M in fiscal 2010.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$967.58M | – |
| FY2024 | Dec 31, 2024 | -$705.81M | – |
| FY2023 | Dec 31, 2023 | -$549.54M | – |
| FY2022 | Dec 31, 2022 | -$410.32M | – |
| FY2021 | Dec 31, 2021 | -$370.59M | – |
| FY2020 | Dec 31, 2020 | -$225.59M | – |
| FY2019 | Dec 31, 2019 | -$292.92M | – |
| FY2018 | Dec 31, 2018 | -$271.07M | – |
| FY2017 | Dec 31, 2017 | -$162.62M | – |
| FY2016 | Dec 31, 2016 | -$150.91M | – |
| FY2015 | Dec 31, 2015 | -$104.15M | – |
| FY2014 | Dec 31, 2014 | -$69.77M | – |
| FY2013 | Dec 31, 2013 | -$47.49M | – |
| FY2012 | Dec 31, 2012 | -$31.30M | – |
| FY2011 | Dec 31, 2011 | -$31.18M | – |
| FY2010 | Dec 31, 2010 | -$7.72M | – |
| FY2009 | Dec 31, 2009 | -$11.01M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$42.09M | – |
| Q2 FY2026 | Jun 30, 2026 | -$95.09M | – |
| Q1 FY2026 | Mar 31, 2026 | -$226.22M | – |
| Q4 FY2025 | Dec 31, 2025 | -$264.19M | – |
| Q3 FY2025 | Sep 30, 2025 | -$222.18M | – |
| Q2 FY2025 | Jun 30, 2025 | -$209.05M | – |
| Q1 FY2025 | Mar 31, 2025 | -$272.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$202.75M | – |
| Q3 FY2024 | Sep 30, 2024 | -$184.61M | – |
| Q2 FY2024 | Jun 30, 2024 | -$129.74M | – |
| Q1 FY2024 | Mar 31, 2024 | -$188.71M | – |
| Q4 FY2023 | Dec 31, 2023 | -$132.97M | – |
| Q3 FY2023 | Sep 30, 2023 | -$139.19M | – |
| Q2 FY2023 | Jun 30, 2023 | -$127.68M | – |
| Q1 FY2023 | Mar 31, 2023 | -$149.70M | – |
| Q4 FY2022 | Dec 31, 2022 | -$107.84M | – |
| Q3 FY2022 | Sep 30, 2022 | -$90.41M | – |
| Q2 FY2022 | Jun 30, 2022 | -$105.21M | – |
| Q1 FY2022 | Mar 31, 2022 | -$106.86M | – |
| Q4 FY2021 | Dec 31, 2021 | -$85.27M | – |
| Q3 FY2021 | Sep 30, 2021 | -$76.93M | – |
| Q2 FY2021 | Jun 30, 2021 | -$78.93M | – |
| Q1 FY2021 | Mar 31, 2021 | -$129.46M | – |
| Q4 FY2020 | Dec 31, 2020 | -$67.73M | – |
| Q3 FY2020 | Sep 30, 2020 | -$59.42M | – |
| Q2 FY2020 | Jun 30, 2020 | -$37.83M | – |
| Q1 FY2020 | Mar 31, 2020 | -$60.61M | – |
| Q4 FY2019 | Dec 31, 2019 | -$57.44M | – |
| Q3 FY2019 | Sep 30, 2019 | -$66.96M | – |
| Q2 FY2019 | Jun 30, 2019 | -$90.64M | – |
| Q1 FY2019 | Mar 31, 2019 | -$77.88M | – |
| Q4 FY2018 | Dec 31, 2018 | -$73.19M | – |
| Q3 FY2018 | Sep 30, 2018 | -$67.34M | – |
| Q2 FY2018 | Jun 30, 2018 | -$57.76M | – |
| Q1 FY2018 | Mar 31, 2018 | -$72.78M | – |
| Q4 FY2017 | Dec 31, 2017 | -$49.92M | – |
| Q3 FY2017 | Sep 30, 2017 | -$38.69M | – |
| Q2 FY2017 | Jun 30, 2017 | -$36.68M | – |
| Q1 FY2017 | Mar 31, 2017 | -$37.33M | – |
| Q4 FY2016 | Dec 31, 2016 | -$58.73M | – |
See a number that looks wrong?